Nektar Therapeutics [NKTR] stock prices are down -2.58% to $0.93 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NKTR shares have gain 4.53% over the last week, with a monthly amount glided 1.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on January 08, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $4. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 10, 2024, and set its price target to $6.50. On November 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $7 on the stock. Rodman & Renshaw initiated its recommendation with a Buy and recommended $2 as its price target on June 28, 2024. In a note dated November 09, 2023, TD Cowen upgraded an Outperform rating on this stock.
The stock price of Nektar Therapeutics [NKTR] has been fluctuating between $0.63 and $1.93 over the past year. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 1701.08% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
The Nektar Therapeutics [NASDAQ:NKTR] reported sales of 93.14M for trailing twelve months, representing a drop of -0.08%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9046 points at the first support level, and at 0.8771 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9798, and for the 2nd resistance point, it is at 1.0275.
Ratios To Look Out For
It’s worth pointing out that Nektar Therapeutics [NASDAQ:NKTR]’s Current Ratio is 4.24. As well, the Quick Ratio is 4.24, while the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 1.85, the price to book ratio is 3.52.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Feb 19 ’25 when 10300.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Feb 19 ’25 to sell 11040.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 23774.0 shares on Feb 19 ’25.
